BILLERICA, Mass., Nov. 22, 2016 /PRNewswire/ -- Bruker today
announced that it has completed the acquisition of the preclinical
PET imaging business of Oncovision, a leading provider of
innovative medical imaging devices. Bruker had previously
announced an agreement to acquire this business in September 2016. Financial terms were not
disclosed.
The recently introduced, next-generation AlbiraSi™
preclinical PET/SPECT/CT system features advanced silicon
photomultiplier (SiPM) technology. This proprietary detector
technology allows the highest full field-of-view PET resolution and
sensitivity, a major advantage over traditional PET technology.
This innovation has also allowed the development of the first
SiPM-based PET insert for preclinical MRI systems, giving
researchers the benefit of simultaneous PET and MRI measurements.
Dr. Wulf I. Jung, President of
Bruker's Preclinical Imaging Division, stated: "PET imaging
is one of the most important imaging modalities for translational
research. With this acquisition Bruker is strengthening its
leadership in preclinical imaging. The unique,
performance-leading SiPM PET detector technology, and other PET
capabilities developed in close collaboration with the molecular
imaging institute I3M and the University of Valencia, offer outstanding spatial resolution
across the full field of view (FOV), increasing the high-resolution
FOV by an order of magnitude compared to traditional PET systems,
and thereby facilitating quantitative imaging investigations."
Frank H. Laukien, Ph.D.,
President and CEO of Bruker Corporation, commented: "Bruker
continues to invest and position itself for sustainable growth in
the important preclinical imaging market. We are very pleased
with this advanced technology acquisition, and believe that our
unique PET/MRI and PET/SPECT/CT systems will significantly advance
quantitative, highest resolution PET translational research."
About Bruker Corporation (NASDAQ: BRKR)
For more than
50 years, Bruker has enabled scientists to make breakthrough
discoveries and develop new applications that improve the quality
of human life. Bruker's high-performance scientific research
instruments and high-value analytical solutions enable scientists
to explore life and materials at molecular, cellular and
microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, in
microscopy, nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information:
www.bruker.com/preclinicalimaging
Investor
contact:
Miroslava
Minkova
Head of Investor
Relations
Bruker
Corporation
T: +1 (978) 663-3660,
ext. 1479
E:
Miroslava.Minkova@bruker.com
|
Media
contact:
Dr. Thorsten
Thiel
Head of Group Marketing
Bruker BioSpin Group
T: +49 (0)721–5161, ext. 6500
E: thorsten.thiel@bruker.com
|
Photo - http://photos.prnewswire.com/prnh/20161121/441667
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bruker-completes-acquisition-of-preclinical-pet-imaging-business-300367101.html
SOURCE Bruker Corporation